Ronny Drapkin

BRCA1 supports XIST RNA concentration on the inactive X chromosome.

The ubiquitin ligase activity in the DDB2 and CSA complexes is differentially regulated by the COP9 signalosome in response to DNA damage.

Unilateral transverse arm defect with subterminal digital nubbins.

The BRCA1-associated protein BACH1 is a DNA helicase targeted by clinically relevant inactivating mutations.

Association of BRCA1 with the inactive X chromosome and XIST RNA.

Expression of candidate tumor markers in ovarian carcinoma and benign ovary: evidence for a link between epithelial phenotype and neoplasia.

Dicer-deficient mouse embryonic stem cells are defective in differentiation and centromeric silencing.

Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas.

The distal fallopian tube: a new model for pelvic serous carcinogenesis.

A recurrent mutation in PALB2 in Finnish cancer families.

Further evidence for BRCA1 communication with the inactive X chromosome.

Lessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancer.

Distinctive cytogenetic profile in benign metastasizing leiomyoma: pathogenetic implications.

Serous carcinogenesis in the fallopian tube: a descriptive classification.

A molecular signature of gastric metaplasia arising in response to acute parietal cell loss.

A candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutations.

Does the fimbria have an embryologic origin distinct from that of the rest of the fallopian tube?

Use of yeast-secreted in vivo biotinylated recombinant antibodies (Biobodies) in bead-based ELISA.

Adenofibroma of the fimbria: a common entity that is indistinguishable from ovarian adenofibroma.

A novel breast cancer-associated BRIP1 (FANCJ/BACH1) germ-line mutation impairs protein stability and function.

Urokinase-type plasminogen activator receptor: a beacon of malignancy?

New insights into the pathogenesis of serous ovarian cancer and its clinical impact.

Regression of drug-resistant lung cancer by the combination of rosiglitazone and carboplatin.

Ovarian cancer pathogenesis: a model in evolution.

Tubal and ovarian pathways to pelvic epithelial cancer: a pathological perspective.

Overexpression of elafin in ovarian carcinoma is driven by genomic gains and activation of the nuclear factor kappaB pathway and is associated with poor overall survival.

An activated ErbB3/NRG1 autocrine loop supports in vivo proliferation in ovarian cancer cells.

PAX8 reliably distinguishes ovarian serous tumors from malignant mesothelioma.

53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers.

STICS, SCOUTs and p53 signatures; a new language for pelvic serous carcinogenesis.

Modeling high-grade serous ovarian carcinogenesis from the fallopian tube.

A comprehensive analysis of PAX8 expression in human epithelial tumors.

Stathmin 1, a marker of PI3K pathway activation and regulator of microtubule dynamics, is expressed in early pelvic serous carcinomas.

Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer.

Aberrant expression of the dendritic cell marker TNFAIP2 by the malignant cells of Hodgkin lymphoma and primary mediastinal large B-cell lymphoma distinguishes these tumor types from morphologically and phenotypically similar lymphomas.

High throughput interrogation of somatic mutations in high grade serous cancer of the ovary.

Rethinking ovarian cancer: recommendations for improving outcomes.

The role of peritoneal cytology at risk-reducing salpingo-oophorectomy (RRSO) in women at increased risk of familial ovarian/tubal cancer.

Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy.

Correlation of serum HE4 with tumor size and myometrial invasion in endometrial cancer.

The new face of ovarian cancer modeling: better prospects for detection and treatment.

ErbB2, EphrinB1, Src Kinase and PTPN13 Signaling Complex Regulates MAP Kinase Signaling in Human Cancers.